L3VLUP
ProSign in

PTGX in the 13F filings

Protagonist Therapeutics Inc · CUSIP 74366E102

Sector · Pharmaceuticals and biotechnologyTheme · Healthcare: biopharma and medtech· L3VLUP-definedTheme · Pharmaceutical preparations
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023
Quarter end
30 Sep 2024
the date the book describes
Filed
14 Nov 2024
latest of these filings; the earliest 12 Nov 2024
Managers listing it
3
at least, of 95 tracked, among listed positions
Comparable managers
94
filed both Q2 2024 and Q3 2024; 2 listed it in both
Shares listed
6,353,507
combined, among listed positions
Reported value
$286m
combined, at the quarter end

Among the 94 comparable managers: 2 buyers (opened or added shares) and 1 seller (trimmed or exited), at least, among listed positions. Their net change in shares is not known from listed positions, because at least one of them lists it in only one of the two quarters.

Managers listing PTGX in Q3 2024

Share of 13F value is the position’s reported value over everything the manager reported that quarter. The share change is against Q2 2024, and only where both filings list the position. A rise in value with no rise in shares is the price, not buying.

3 of 3 holders

ActionFiling
Farallon Capital Management LLC5,861,006$264m1.16%Added+20,23314 Nov 2024 (the filing on sec.gov)
Woodline Partners LP466,518$21m0.18%Trimmed-355,65514 Nov 2024 (the filing on sec.gov)
Winton Group Ltd25,983$1.2m0.08%Newnew12 Nov 2024 (the filing on sec.gov)

Largest increases and reductions, by shares

Q2 2024 to Q3 2024, among managers that listed it in both quarters or opened it.

Increases

Reductions

New positions and exits

At least these many: a manager is shown exiting only where its own filing shows the position gone.

New (1)

Exited (0)

No exit shown by a manager’s own filing.

Ownership over time

Every quarter on file. A quarter-end value moves with the price as well as with the shares held; buyers and sellers count comparable managers, by shares.
3 in Q3 2024 to 7 in Q2 2026

Tracked managers listing it, at least.

0358102017201820192020202120222023202420252026
the quarter shown share split complete books; unmarked quarters rest on listed positionsClick a quarter to open it.
PTGX by quarter
QuarterHoldersReported valueBuyersSellers
Q1 20171$231kn.a.n.a.
Q2 20171$197kn.a.n.a.
Q3 20171$458kn.a.n.a.
Q4 20172$19mn.a.n.a.
Q1 20181$8.7mn.a.n.a.
Q2 20182$6.5mn.a.n.a.
Q3 20181$23mn.a.n.a.
Q4 20182$15mn.a.n.a.
Q1 20192$23mn.a.n.a.
Q2 20193$20mn.a.n.a.
Q3 20192$18mn.a.n.a.
Q4 20191$11mn.a.n.a.
Q1 20201$11mn.a.n.a.
Q2 20202$48mn.a.n.a.
Q3 20201$54mn.a.n.a.
Q4 20202$60mn.a.n.a.
Q1 20212$87mn.a.n.a.
Q2 20212$156mn.a.n.a.
Q3 20214$130mn.a.n.a.
Q4 20214$169mn.a.n.a.
Q1 20223$110mn.a.n.a.
Q2 20225$67mn.a.n.a.
Q3 20223$53mn.a.n.a.
Q4 20225$52mn.a.n.a.
Q1 20234$116mn.a.n.a.
Q2 20235$171mn.a.n.a.
Q3 20232$109mn.a.n.a.
Q4 20232$191m20
Q1 20245$248m41
Q2 20243$262m22
Q3 20243$286m21
Q4 20244$253m30
Q1 20254$354m31
Q2 20255$425m41
Q3 20258$790m80
Q4 202510$1.3bn1414
Q1 20269$1.8bn1610
Q2 20267$1.9bn1410

Compare with…

Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.

PTGX and LLY →PTGX and JNJ →PTGX and VRTX →Choose a stock to compare with PTGX →

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.

Which funds own PTGX, latest filings →Back to the 13F Explorer →